Voydeya^® (danicopan)

Louisville, KY — April 8, 2024 — Onco360^®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Alexion Pharmaceuticals for Voydeya^® (Danicopan) as a first in class oral, Factor D inhibitor. It is FDA-approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in combination with C5 inhibitor, Ultomiris^® (Ravulizumab) or Soliris^® (Eculizumab) for patients that experience clinically significant extravascular hemolysis (EVH).1 Voydeya^® is an oral, Factor D inhibitor that acts in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels.

“Onco360 appreciates the opportunity to partner further with the team at Alexion and become the sole national specialty pharmacy provider for Voydeya^®”, said Benito Fernandez, Chief Commercial Officer. “We are proud to add this first in class oral Factor D inhibitor treatment option for PNH patients.”

For more information about Voydeya, please refer to Alexion’s press release.

Please see the full Prescribing Information for Voydeya^®

Media Contact: Benito Fernandez, Chief Commercial Officer

[email protected]

516-640-1332

Reference:

1. Voydeya Prescribing Information. Boston, MA: Alexion Pharmaceutical Corp; March 2024.